3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Recurrence
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced Pancreatic Cancer
1
Interventions
pembrolizumab
13
Gemcitabine
12
Cyclophosphamide
10
Carboplatin
10
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Cisplatin
8
Docetaxel
7
X-Rays
6
Filgrastim
6
Doxorubicin
6
Biopsy
6
tislelizumab
5
Radiosurgery
5
Phantoms, Imaging
5
Paclitaxel
5
Nivolumab
5
Irinotecan
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
spartalizumab
4
palbociclib
4
Thiotepa
4
Temozolomide
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Mesna
4
Ipilimumab
4
Imatinib Mesylate
4
Ifosfamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
pegylated granulocyte colony-stimulating factor
×
Gastrointestinal
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled